Sign up for a free trial and join thousands of other leading professionals. Click here to start!

Adenocarcinoma News

Home | Index > Health > Cancer > Adenocarcinoma

TAKE THIS POLL
Is Belgian Prime Minister Herman Van Rompuy the right person to lead the EU as its president? (Nov. 20, 2009) Yes. No. Don't know.

Sort by: relevance (24 hours) relevance date

Study highlights from November issue of GIE: Gastrointestinal Endoscopy 23 Nov 2009 16:52 GMT
... and prognosis than the more common type of pancreatic cancer of the pancreas glands (adenocarcinoma). Determination of malignant (cancerous) potential through specimens obtained by EUS-FNA can help in the ...
Pancreatic Cancer Prevention: Recent findings in pancreatic cancer prevention described by researchers from University of Massachusetts 22 Nov 2009 05:15 GMT
... detailed in a study published in . "Blacks have a higher incidence of pancreatic adenocarcinoma and worse outcomes compared to whites. Identifying barriers in care may explain survival differences ...
Gastric Cancer: New findings from Memorial Sloan Kettering Cancer Center, Department of Surgery in the area of gastric cancer published 19 Nov 2009 05:35 GMT
... 4/19 resected cases; 2/4 were detected on preoperative biopsies. All cases with coexisting gastric adenocarcinoma had larger carcinoid tumors and more advanced carcinoid disease. The DSS is excellent for ...
Asuragen to present at Association for Molecular Pathology 15th Annual Meeting 19 Nov 2009 09:20 GMT
... standardization of quantitative BCR/ABL1 testing. "Evaluation of MicroRNA Signatures for Identification of Pancreatic Ductal Adenocarcinoma in FFPE specimens and Fine Needle Aspirates of Pancreas." (Abstract No. ST25) - Differential ...
Asuragen to present at Association for Molecular Pathology 15th Annual Meeting (BIZ) 19 Nov 2009 09:27 GMT
... standardization of quantitative BCR/ABL1 testing. "Evaluation of MicroRNA Signatures for Identification of Pancreatic Ductal Adenocarcinoma in FFPE specimens and Fine Needle Aspirates of Pancreas." (Abstract No. ST25) - Differential ...

YM BIOSCIENCES REPORTS CYT997 ORAL VASCULAR DISRUPTING AGENT RESULTS PRESENTED AT AACR-NCI-EORTC MEETING 17 Nov 2009 12:31 GMT
... low doses), CYT997 is able to produce potent vascular disrupting effects in tumors (colon adenocarcinoma xenograft model), and in combination with cisplatin dosed weekly leads to enhanced antitumor effects ...
YM BIOSCIENCES REPORTS CYT997 ORAL VASCULAR DISRUPTING AGENT RESULTS PRESENTED AT AACR-NCI-EORTC MEE 17 Nov 2009 12:34 GMT
... low doses), CYT997 is able to produce potent vascular disrupting effects in tumors (colon adenocarcinoma xenograft model), and in combination with cisplatin dosed weekly leads to enhanced antitumor effects ...
YM BioSciences presents preclinical results of its small molecule VDA at the AACR-NCI-EORTC conference 17 Nov 2009 13:55 GMT
... low doses), CYT997 is able to produce potent vascular disrupting effects in tumors (colon adenocarcinoma xenograft model), and in combination with cisplatin dosed weekly leads to enhanced antitumor effects ...
Dendreon Receives FDA Acknowledgement of Complete Response 20 Nov 2009 13:52 GMT
... company received in 2007. The BLA includes data from the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) trial, which was conducted under a Special Protocol Assessment agreement with the FDA. ...
FDA acknowledges Dendreon's amended BLA for PROVENGE as a complete response 20 Nov 2009 14:56 GMT
... company received in 2007. The BLA includes data from the IMPACT (IMmunotherapy for Prostate AdenoCarcinoma Treatment) trial, which was conducted under a Special Protocol Assessment agreement with the FDA. ...

Not satisfied with this news section? Make your own with the Newsletter Manager or try our other media monitoring services.

New Cervical Cancer Vaccine and Revised Indications for Gardasil 18 Nov 2009 19:52 GMT
... indicated for prevention of cervical cancer, cervical intraepithelial neoplasia grade 2 or worse and adenocarcinoma in situ, and cervical intraepithelial neoplasia grade 1, caused by oncogenic human papillomavirus types ...
Mesothelioma Researchers Find Biological Marker to Help Diagnose Malignant Mesothelioma 21 Nov 2009 04:30 GMT
... positivity is helpful in differentiation of MM [malignant mesothelioma] from pleural involvement of pulmonary adenocarcinoma, so we suggest that it should be included in the IHC [immunohistochemical] panel used ...
Cancer Therapy: Reports outline cancer therapy study results from Fukuoka University, National Kyushu Cancer Center 19 Nov 2009 06:15 GMT
... Publishing Inc., 350 Main St., Malden, MA 02148, USA. Keywords: Japan, Fukuoka, Cancer Therapy, Adenocarcinoma, Hormones, Men's Health, Oncology, Prostate Cancer, Prostate Carcinoma, Prostatic Neoplasms, Therapy, Treatment. This article ...
Exelixis reports promising data from Phase I study of XL147 in patients with advanced solid tumours 19 Nov 2009 13:58 GMT
... tumours in an ongoing single-agent Phase I trial of XL147. The patient with cervical adenocarcinoma, who experienced a PR, had biomarker reductions ranging from 69% to 76%, and a ...
Father Brian's death "imminent" 19 Nov 2009 20:19 GMT
... contributed to his terminal illness from two types of cancer, chronic lymphocytic cancer and adenocarcinoma. Father Brian has spent the past 37 years serving WA. In July, he told ...
YM proposed partner releases results for CYT997 17 Nov 2009 15:12 GMT
... low doses) CYT997 is able to produce potent vascular disrupting effects in tumours (colon adenocarcinoma xenograft model) and in combination with cisplatin, dosed weekly leads to enhanced anti-tumour effects ...
Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference (BIZ) 17 Nov 2009 17:50 GMT
... tumors in an ongoing single-agent phase 1 trial of XL147. The patient with cervical adenocarcinoma, who experienced a PR, had biomarker reductions ranging from 69% to 76%, and a ...
AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AA 17 Nov 2009 17:50 GMT
... rapamycin, as single agents and in combination, in a genetically engineered HER2 driven breast adenocarcinoma model were also presented at the meeting. Data indicate that tivozanib and rapamycin each ...
Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference 17 Nov 2009 17:50 GMT
... tumors in an ongoing single-agent phase 1 trial of XL147. The patient with cervical adenocarcinoma, who experienced a PR, had biomarker reductions ranging from 69% to 76%, and a ...
AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting 17 Nov 2009 17:51 GMT
... rapamycin, as single agents and in combination, in a genetically engineered HER2 driven breast adenocarcinoma model were also presented at the meeting. Data indicate that tivozanib and rapamycin each ...

THESE STORIES ARE NOT PUBLISHED BY IPD GROUP, INC. AND THESE LINKS WILL TAKE YOU TO OTHER WEBSITES. SOME OF THESE WEBSITES REQUIRE THEIR OWN REGISTRATION TO READ THEIR STORIES. PLEASE READ THE DISCLAIMER FOR MORE DETAILS. >>>

Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Ca 17 Nov 2009 17:52 GMT
... tumors in an ongoing single-agent phase 1 trial of XL147. The patient with cervical adenocarcinoma, who experienced a PR, had biomarker reductions ranging from 69% to 76%, and a ...
AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and 17 Nov 2009 17:52 GMT
... rapamycin, as single agents and in combination, in a genetically engineered HER2 driven breast adenocarcinoma model were also presented at the meeting. Data indicate that tivozanib and rapamycin each ...
AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting 17 Nov 2009 17:53 GMT
... rapamycin, as single agents and in combination, in a genetically engineered HER2 driven breast adenocarcinoma model were also presented at the meeting. Data indicate that tivozanib and rapamycin each ...
Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference 17 Nov 2009 17:56 GMT
... tumors in an ongoing single-agent phase 1 trial of XL147. The patient with cervical adenocarcinoma, who experienced a PR, had biomarker reductions ranging from 69% to 76%, and a ...
Preventative Brain Radiation for Lung Cancer Patients: Benefits and Risks 15 Nov 2009 20:51 GMT
... carcinoma, which make up about 25 percent to 30 percent of all lung cancers; adenocarcinoma, which accounts for about 40 percent of lung cancers and is usually found in ...